<span item_type="fundamental" item_id="648e98b34b53281070b23378ca7eea40" counter_id="ST/US/LUCD" env="prod"></span><span item_type="announcement" item_id="648252917040027650" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 1.256 M, missing the estimate of USD 1.383 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.17, missing the estimate of USD -0.085.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -12.18 M.</p><p></p><h4>Revenue</h4><ul><li>For the three months ended March 31, 2026, EsoGuard related revenues were $1.3 million. Revenue was $1,256 thousand for the three months ended March 31, 2026, compared to $828 thousand for the same period in 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/ex99-1.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li>Operating expenses were approximately $13.4 million for the three months ended March 31, 2026, which included stock-based compensation expenses of $1.4 million. Total operating expenses were $13,370 thousand for the three months ended March 31, 2026, compared to $13,315 thousand for the same period in 2025. Net operating expenses were $11,708 thousand for the three months ended March 31, 2026, compared to $11,990 thousand for the same period in 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/ex99-1.htm"></span></li></ul><h4>Other (Income) Expense, Net</h4><ul><li>Other (Income) expense, net was $1,795 thousand for the three months ended March 31, 2026, compared to $14,421 thousand for the same period in 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/ex99-1.htm"></span></li></ul><h4>Net Loss</h4><ul><li>GAAP net loss attributable to common stockholders was approximately - $23.6 million for the three months ended March 31, 2026, inclusive of a deemed Preferred Stock dividend of $9.7 million or - $0.17 per common share. Net Loss was - $13,909 thousand for the three months ended March 31, 2026, compared to - $26,908 thousand for the same period in 2025. Net loss attributable to common stockholders was - $23,628 thousand for the three months ended March 31, 2026, compared to - $36,018 thousand for the same period in 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/ex99-1.htm"></span></li></ul><h4>Non-GAAP Adjusted Loss</h4><ul><li>The non-GAAP adjusted loss for the three months ended March 31, 2026, was approximately - $10.5 million or - $0.07 per common share. Non-GAAP adjusted (loss) was - $10,452 thousand for the three months ended March 31, 2026, compared to - $11,162 thousand for the same period in 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/ex99-1.htm"></span></li></ul><h4>Cash and Cash Equivalents</h4><ul><li>Lucid Diagnostics Inc. had cash and cash equivalents of $27.9 million as of March 31, 2026, compared to $34.7 million as of December 31, 2025. The company ended Q1 2026 with $45 million in proforma cash, extending its runway into 2027. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/ex99-1.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li>Lucid Diagnostics Inc. processed 3,177 EsoGuard® tests in Q1 2026. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/ex99-1.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>Lucid Diagnostics Inc. aims to build commercial momentum for EsoGuard by generating consistent demand and progressing Medicare and VA targeting efforts. The company plans to expand engagement with health systems and commercial payors. This strategy positions Lucid Diagnostics Inc. to convert EsoGuard demand to revenue and accelerate commercialization as key reimbursement milestones are achieved. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/ex99-1.htm"></span></li></ul>

Lucid Diagnostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.256 M